Crowdonomics
All companies
Eclipse Diagnostics logo

Eclipse Diagnostics

Operating

Eclipse Diagnostics Inc.

Biotech · Los Angeles, CA

Grower-friendly cannabis test Handheld Cannabis Testing Device

Post-money valuation
$11.4M
As of Apr 2020 · from Reg CF Offering (2019) · pre-money + amount raised, not a traded price
Total raised
$358,176
Across 2 rounds since 2018
Latest share price
$11.00
Reg CF Offering (2019) offering price

Financials

FY2015–FY2019 · from SEC filings · hover any figure for its source
$0
2015
$0
2016
$0
2017
$0
−$147K
2018
$0
−$158K
2019
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2015
FY2016
FY2017
FY2018
FY2019
Income statement
Revenue
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
Net income
$0
$0
$0
-$146,628
-$158,280
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$0
$0
$0
$8,952
$1,346
Accounts receivable
$0
$0
$0
$0
$5,475
Total assets
$0
$0
$0
$12,666
$12,494
Short-term debt
$0
$0
$0
$5,775
$8,364
Long-term debt
$0
$0
$0
$0
$0
Total liabilities
$0
$0
$0
$5,775
$8,364
Other
Headcount
2
1
1

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$10.2M
post-money
$11.4M
post-money
Reg CF Offering (2018)
Reg CF Offering (2019)

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Reg CF Offering (2019)ClosedReg CF · Common Equity · via StartEngine
Raised $179.1K / $363.2KInvestors 151Post-money $11.4M
Reg CF Offering (2018)ClosedReg CF · Common Equity · via StartEngine
Raised $179.1K / $1.1MInvestors 94Post-money $10.2M

Team

4 people
Luka FajsFounder
President, CEO, Director

Luka comes from Slovenia and holds a PhD in Medical Microbiology from the University of Ljubljana, Slovenia. Before starting the Company, he was doing research and clinical laboratory diagnostics of hemorrhagic fevers, biothreats and other infectious diseases. He spent a lot of time in the field, helping doctors and nurses in low-income countries to set up and improve their diagnostic preparedness. During his work, he saw first-hand the drawbacks of the existing medical diagnostics system that is mostly centralized, capital-intensive and many people do not have adequate access to it. That was the motivation to join Prof. Robert’s laboratory in Singapore where he took over the fundraising and startup activities of the technology. He continued as CEO of Biosensorix and helped secure early funding and directed the research and development activities. He is a passionate entrepreneur with a deep knowledge of diagnostics, user expectations, and basic science. Jan 2014 - Dec 2014: Post-doc at Institute of Microbiology and Immunology, University of Ljubljana, Slovenia - research and clinical diagnostics of viral hemorrhagic fevers and other zoonoses Jan 2015 - Dec 2016: Post-doc at Nanyang Technological University, Singapore - research and development of diagnostic and environmental monitoring platforms Nov 2015 - present: cofounder, CEO and Director of Biosensorix Pte. Ltd., Singapore - research and development of medical devices for rapid detection and quantification of disease biomarkers Feb 2018 - present: cofounder, president, CEO and Director of Eclipse Diagnostics Inc., USA - research and development of medical devices for rapid detection and quantification of disease biomarkers

Prof. Robert S. MarksFounder
Chief Scientist, Director

Prof. Dr. Robert S. Marks is the co-inventor of the technological platform and is a renowned expert and key opinion leader in the field of biosensors. He is a Full Professor at the Ben-Gurion University of the Negev, Israel, at the Department of Biotechnology Engineering, The National Institute for Biotechnology in the Negev and the Ilse Kats Centre for Nanotechnology. He was a Visiting Scientist in the NTU-MSE, and was a program coordinator for the NRF CREATE program "Nanomaterials for Water and Energy Management". Robert has previously co-founded Biosensing Technologies Ltd, Biopixel Ltd and Polyrizon Ltd. He will be assisting with advising the development of the next generation prototype and establishing the business collaboration with potential partners. Prof. Marks has extensive experience in development of biosensors. He is the Editor-in-Chief of a 2007 2-volume Wiley Handbook in Biosensors and Biochips and a 2014 Viral Diagnostics book for virus detection. He is the author of 150+ papers (H-index 27), and numerous chapters. He has 4 issued patents as well as a dozen filed. 2011-present: Full Professor at Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Israel Jan 2012 - Dec 2016: Visiting Professor at Nanyang Technological University, Singapore July 2011 - Jun 2016: Coordinator at NRF (National Research Foundation) CREATE Center for Nanomaterials for Energy and Water Management, Singapore Nov 2015 - present: cofounder and Director of Biosensorix Pte. Ltd., Singapore - research and development of medical devices for rapid detection and quantification of disease biomarkers Feb 2018 - present: cofounder and Director of Eclipse Diagnostics Inc., USA - research and development of medical devices for rapid detection and quantification of disease biomarkers

Tina Semolic
Marketing Advisor

Marketing advisor at Biosensorix Pte. Ltd. Previously at Adglow.com (clients: Prada, Miu Miu, Moschino, Pinko, Max Mara, Armani ect.), Httpool.com (over 50 clients: Generali insurance, Mercedes, Audi, STO - Slovenian touristic org. ect.), Adroll.com (Head of Business Development SMB) Facebook.com (over 500 clients: Adidas, Nike, Ferrari, illy, Morellato, Fossil, Head, Hugs ect.)

Robert S Marks
Director and Secretary

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 2 of 9 annual reports (FY2017–FY2025)

151 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-UOct 7, 20220001665160-22-002701
    EDGAR
  • Form C-ARJun 15, 20200001665160-20-000818
    EDGAR
  • Form C-UMay 5, 20200001665160-20-000565
    EDGAR
  • Form C/AMar 9, 20200001665160-20-000205
    EDGAR
  • Form C/AJan 7, 20200001665160-20-000016
    EDGAR
  • Form C/ANov 6, 20190001665160-19-001119
    EDGAR
  • Form C/ASep 6, 20190001665160-19-000916
    EDGAR
  • Form C/AJul 8, 20190001665160-19-000775
    EDGAR
Source: ManualCIK 0001733206DEShare price $11.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.